MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
NanoVibronix Cost of Revenue 2011-2026 | NAOV
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue NanoVibronix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.05 M | 746 K | 585 K | 925 K | 409 K | 249 K | 158 K | 88 K | 88 K | 49 K | 93 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.05 M | 49 K | 404 K |
Quarterly Cost of Revenue NanoVibronix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 533 K | 529 K | 656 K | - | 243 K | 389 K | 257 K | - | 109 K | 78 K | 119 K | - | 17 K | 204 K | 166 K | - | 271 K | 110 K | 26 K | - | 51 K | 231 K | 63 K | - | 54 K | 56 K | 26 K | - | 46 K | 55 K | 22 K | - | 22 K | 18 K | 16 K | - | 27 K | 22 K | 27 K | - | 10 K | 15 K | 10 K | - | 35 K | 25 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 656 K | 10 K | 130 K |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.18 | 1.87 % | $ 3.4 M |  USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 10.73 | 2.98 % | $ 1.45 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.14 | 5.88 % | $ 876 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 8.52 | 1.67 % | $ 612 M |  Israel |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.66 | -2.0 % | $ 1.14 B | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 12.71 | 0.87 % | $ 1.91 B | USA |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.69 | 6.15 % | $ 37.6 M | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.16 | 4.95 % | $ 155 M |  France |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 71.56 | 2.54 % | $ 106 B | USA |
 |
Establishment Labs Holdings
ESTA
|
64.8 M | $ 65.03 | 2.43 % | $ 1.93 B |  Costa-rica |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
InMode Ltd.
INMD
|
79.5 M | $ 13.64 | 1.56 % | $ 882 M | Israel |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 11.14 | 1.0 % | $ 301 M | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.34 | 0.77 % | $ 21.6 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.19 | -0.23 % | $ 1.33 M | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 61.86 | 0.7 % | $ 3.37 B |  Britain |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
MiMedx Group
MDXG
|
73 M | $ 4.5 | 1.93 % | $ 665 M | USA |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 111.24 | 1.17 % | $ 194 B | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 9.82 | 0.05 % | $ 352 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 265.0 | 1.44 % | $ 7.48 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
21.9 M | $ 2.56 | -1.16 % | $ 150 M | Israel |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 9.27 | 2.89 % | $ 714 M | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 32.87 | 0.08 % | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 175.45 | 3.54 % | $ 13.1 B | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 33.48 | 2.18 % | $ 4.99 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
19.8 M | $ 3.86 | 5.07 % | $ 159 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 17.24 | 0.76 % | $ 404 M | USA |